Loading [MathJax]/jax/output/PreviewHTML/jax.js
Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 29;12(11):1034.
doi: 10.3390/pharmaceutics12111034.

Electro-Hydrodynamic Drop-on-Demand Printing of Aqueous Suspensions of Drug Nanoparticles

Affiliations

Electro-Hydrodynamic Drop-on-Demand Printing of Aqueous Suspensions of Drug Nanoparticles

Ezinwa Elele et al. Pharmaceutics. .

Abstract

We demonstrate the ability to fabricate dosage forms of a poorly water-soluble drug by using wet stirred media milling of a drug powder to produce an aqueous suspension of nanoparticles and then print it onto a porous biocompatible film. Contrary to conventional printing technologies, a deposited material is pulled out from the nozzle. This feature enables printing highly viscous materials with a precise control over the printed volume. Drug (griseofulvin) nanosuspensions prepared by wet media milling were printed onto porous hydroxypropyl methylcellulose films prepared by freeze-drying. The drug particles retained crystallinity and polymorphic form in the course of milling and printing. The versatility of this technique was demonstrated by printing the same amount of nanoparticles onto a film with droplets of different sizes. The mean drug content (0.19-3.80 mg) in the printed films was predicted by the number of droplets (5-100) and droplet volume (0.2-1.0 µL) (R2 = 0.9994, p-value < 10-4). Our results also suggest that for any targeted drug content, the number-volume of droplets could be modulated to achieve acceptable drug content uniformity. Analysis of the model-independent difference and similarity factors showed consistency of drug release profiles from films with a printed suspension. Zero-order kinetics described the griseofulvin release rate from 1.8% up to 82%. Overall, this study has successfully demonstrated that the electro-hydrodynamic drop-on-demand printing of an aqueous drug nanosuspension enables accurate and controllable drug dosing in porous polymer films, which exhibited acceptable content uniformity and reproducible drug release.

Keywords: biocompatible films; drop-on-demand printing; drug release profile; nanoparticles; poorly water-soluble drugs; precision dosage form.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Suspension shear viscosity vs. shear rate.
Figure 2
Figure 2
Frequency dependence of the suspension electric properties: (a) real part of complex permittivity ɛ’; (b) imaginary part of complex permittivity ɛ”; (c) specific conductivity , where f is the field frequency in Hz and ε0=8.85×1012F/m is the vacuum permittivity.
Figure 3
Figure 3
EHD DOD concept: (a) printing device: 1, infused fluid volume vi; 2, insulating nozzle; 3, energized electrode; 4, suspension, 5, porous polymer film; 6, insulator; 7, ground electrode; 8, 3D-movable stage; 2ROD, the nozzle outer diameter; H, the separation between the electrodes; h, the film thickness, and Up, tp are the peak and length of a voltage pulse applied to the electrodes. (b) Three-step printing process: (1) a fluid volume is infused into the nozzle to form a pendant droplet, (2) an electric force generated by an applied voltage stretches the droplet to form a liquid bridge anchored to the nozzle exit and the film, (3) the liquid bridge breaks up, creating a sessile droplet on the film and the other hanging from the nozzle. Adapted with permission from [19], Elsevier, 2012.
Figure 4
Figure 4
Printing 0.5-μL droplets of 2.5% HPMC-griseofulvin suspension onto 92%-porous HPMC film: (a) dispensing of a droplet, (b) 20.6-mg porous HPMC film before (left) and after (right) printing of fifty 0.5-μL droplets.
Figure 5
Figure 5
DSC curves of specimens overlaid on the temperature range 200–240 °C: (a) as-received griseofulvin powder (0.5 mg); (b) 3.5-mg porous HPMC film with five printed 0.5-µL droplets of 2.5% HPMC-griseofulvin-suspension (calculated griseofulvin content 0.45 mg); (c) porous HPMC film (3 mg) without the suspension.
Figure 6
Figure 6
X-ray diffractograms: (a) griseofulvin reference pattern in the instrument library; (b) as-received griseofulvin powder (4.5 mg); (c) 20-mg porous HPMC film with 50 printed 0.5-µL droplets of 2.5% HPMC-griseofulvin suspension (calculated griseofulvin content 4.51 mg); (d) porous HPMC film (20 mg) without the suspension.
Figure 7
Figure 7
Curves of the HPMC matrix weight percentage vs. temperature for (1–3) (2.5 ± 0.3)-mg porous films with 5 printed 0.5-µL droplets of 2.5% HPMC-griseofulvin suspension (calculated griseofulvin content 0.45 mg) after overnight storage in a desiccator at room temperature and for (4–6) (2.5 ± 0.3)-mg porous films without the suspension.
Figure 8
Figure 8
Release profiles of griseofulvin from (a) six porous (20.4±0.4)-mg HPMC films, each loaded with 25 µL of 2.5% HPMC-griseofulvin suspension by printing fifty 0.5-µL droplets, and (b) six 25-µL specimens of the same griseofulvin suspension.
Figure 9
Figure 9
Mean drug content predicted by Equation (3) vs. the measured mean drug content in the printed films. Note that Nd×Vd was set at 1, 2, 4, 8, 12, 16, and 20 µL to attain 7 different levels of drug content presented in the figure. The variability observed along the horizontal direction is associated with the use of 29 different NdVd pairs in the experiments.

Similar articles

References

    1. Katsanis S.H., Javitt G., Hudson K. A case study of personalized medicine. Science. 2008;320:53–54. doi: 10.1126/science.1156604. - DOI - PubMed
    1. Govender R., Abrahmsén-Alami S., Larsson A., Folestad S. Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals. Eur. J. Pharm. Biopharm. 2020;149:58–76. doi: 10.1016/j.ejpb.2020.01.001. - DOI - PubMed
    1. Personalized Medicine Coalition Personalized Medicine at FDA: The Scope & Significance of Progress in 2019. [(accessed on 6 September 2020)]; Available online: http://www.personalizedmedicinecoalition.org/Resources/Personalized_Medi....
    1. Norman J., Madurawe R.D., Moor C.M.V., Khan M.A., Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv. Drug Deliv. Rev. 2017;108:39–50. doi: 10.1016/j.addr.2016.03.001. - DOI - PubMed
    1. Trenfield S.J., Awad A., Goyanes A., Gaisford S., Basit A.W. 3D printing pharmaceuticals: Drug development to frontline care. Trends Pharmacol. Sci. 2018;39:440–451. doi: 10.1016/j.tips.2018.02.006. - DOI - PubMed

LinkOut - more resources